SOPHiA GENETICS leaders will talk onsite about the company’s cutting-edge SOPHiA DDM™ Platform

BOSTON and LAUSANNE, Switzerland, May 25, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, will attend the 2023 ASCO Annual Meeting in Chicago, IL, from June 2-6 at booth number 23119. 

In collaboration with UroCCR, the French National Cancer Institute research network for kidney cancer, SOPHiA GENETICS will present a poster session on Saturday, June 3 from 8:00 – 11:00 AM. This session will showcase how kidney cancer recurrence risk scores based on machine learning compare to conventional risk scores. The full abstract can be viewed here. 

In addition, SOPHiA GENETICS executives, including CEO and Co-Founder Jurgi Camblong, will give Ted Talk-style presentations at the company’s booth. Timing and topics include:

• Saturday, June 3 – 2:00 PM 

Peter Casasanto, M.B.A., Chief BioPharma Officer 

Casasanto will speak to how companies can leverage the SOPHiA GENETICS global decentralized network, tailored solutions, and expert guidance to accelerate the pace of precision medicine development.

• Sunday, June 4 – 12:30 PM

Jurgi Camblong, Ph.D., M.B.A., Co-Founder and CEO

Camblong will discuss the future of SOPHiA GENETICS’ SOPHiA DDM™ Platform, pioneering BioPharma solutions, and how machine learning is reshaping the precision medicine journey.                                                             

• Sunday, June 4 – 2:00 PM 

Philippe Menu, M.D., Ph.D., M.B.A, Executive Vice President and Chief Medical Officer 

Menu will provide demos of SOPHiA CarePath^TM , the next-generation model of the SOPHiA DDM™ Platform that will allow users to holistically visualize data from a single patient, including genomic, clinical, biological and radiomic.   

SOPHiA GENETICS executives will be available for one-on-one media conversations about the company’s offerings, including SOPHiA CarePath™, the next-generation model of the SOPHiA DDM™ Platform that will allow users to holistically visualize data from a single patient, including genomic, clinical, biological and radiomic.   

The 2023 ASCO Annual Meeting brings together global cancer experts to discuss and showcase the latest innovations in cancer research and education. This year's program features over 200 sessions complementing Dr. Eric Winer's Presidential theme Partnering With Patients: The Cornerstone of Cancer Care and Research. 

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. 

About SOPHiA GENETICS 
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. Where others see data, we see answers. 

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS Forward-Looking Statements: 

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Media Contact:
Kelly Katapodis
[email protected]